title: Elevated Th22 as well as Th17 cells associated with therapeutic outcome and clinical stage are potential targets in patients with multiple myeloma.
abstract: T helper (Th) cell imbalance plays important roles in tumor development and their effects in Multiple myeloma (MM) remain unclear. In the present study, we investigated the levels and clinical significance of Th22, Th17 and Th1 cells in patients with MM. Th subsets were examined by flow cytometry. Plasma IL-22, IL-17A and IFN-γ concentrations were measured by ELISA. AHR and RORC mRNA expression was examined by RT-PCR. Here, we found that the frequency of Th22 cells was significantly elevated in peripheral blood (PB) and bone marrow (BM) of newly-diagnosed MM patients, and recovered in complete remission patients after chemotherapy. The circulating Th17 cells accompanied by IL-17A levels were also up-regulated in MM patients and decreased after remission. We also found that there was a significantly positive correlation between Th22 and Th17 cells in MM patients. Moreover, the frequencies of Th22 and Th17 cells were higher in stage III than in stage I+II of MM. Our data demonstrated that Th22 and Th17 cells might be important therapeutic targets in multiple myeloma and could facilitate the effect of antitumor immunotherapy.
authors.affiliation: Department of Hematology, Qilu Hospital, Shandong University, Jinan, China.|Department of Hematology, Jinan Central Hospital, Affiliated to Shandong University, Jinan, China.
authors.forename: Min
authors.initials: M
authors.lastname: Wang
authors.affiliation: Department of Hematology, Qilu Hospital, Shandong University, Jinan, China.|Department of Hematology, Jinan Central Hospital, Affiliated to Shandong University, Jinan, China.
authors.forename: Ping
authors.initials: P
authors.lastname: Chen
authors.affiliation: Department of Hematology, Qilu Hospital, Shandong University, Jinan, China.
authors.forename: Yan
authors.initials: Y
authors.lastname: Jia
authors.affiliation: Department of Hematology, Qilu Hospital, Shandong University, Jinan, China.
authors.forename: Na
authors.initials: N
authors.lastname: He
authors.affiliation: Department of Hematology, Jinan Central Hospital, Affiliated to Shandong University, Jinan, China.
authors.forename: Daqi
authors.initials: D
authors.lastname: Li
authors.affiliation: Department of Hematology, Qilu Hospital, Shandong University, Jinan, China.
authors.forename: Chunyan
authors.initials: C
authors.lastname: Ji
authors.affiliation: Department of Hematology, Qilu Hospital, Shandong University, Jinan, China.
authors.forename: Daoxin
authors.initials: D
authors.lastname: Ma
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D051792:Basic Helix-Loop-Helix Proteins / Q000235:genetics / Q000378:metabolism; D014408:Biomarkers, Tumor / Q000097:blood / Q000235:genetics; D018791:CD4 Lymphocyte Count; D016022:Case-Control Studies; D002681:China; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D007371:Interferon-gamma / Q000097:blood; D020381:Interleukin-17 / Q000097:blood; D007378:Interleukins / Q000097:blood; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000097:blood / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology / Q000473:pathology; D009367:Neoplasm Staging; D057132:Nuclear Receptor Subfamily 1, Group F, Member 3 / Q000235:genetics / Q000378:metabolism; D016133:Polymerase Chain Reaction; D012333:RNA, Messenger / Q000378:metabolism; D018336:Receptors, Aryl Hydrocarbon / Q000235:genetics / Q000378:metabolism; D012074:Remission Induction; D016176:T-Lymphocyte Subsets / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism; D058504:Th17 Cells / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism; D016896:Treatment Outcome; D000097043:Interleukin-22
chemical_list: D051792:Basic Helix-Loop-Helix Proteins; D014408:Biomarkers, Tumor; D007371:Interferon-gamma; D020381:Interleukin-17; D007378:Interleukins; D057132:Nuclear Receptor Subfamily 1, Group F, Member 3; D012333:RNA, Messenger; D018336:Receptors, Aryl Hydrocarbon; D000097043:Interleukin-22; C111235:AHR protein, human; C573415:IFNG protein, human; C508717:IL17A protein, human; C539900:RORC protein, human
keywords: Pathology Section; Th1; Th17; Th22; multiple myeloma